AT1R overexpression, which has oncogenic potential in the absence of AngII administration [1], has been documented in the luminal A and B subtypes of BC and correlated with aggressive characteristics, including increased lymph node metastasis (LMN), reduced responsiveness to neoadjuvant therapy (i.e., ET), and reduced overall survival. The gene discussed is AGT; the disease is breast cancer.